Recent Advances in Psychiatric Medications
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 222
Special Issue Editors
Interests: psychiatric epidemiology; mental health; psychopharmacology; suicidology; digital health
Special Issue Information
Dear Colleagues,
According to the World Health Organization (WHO), mental health disorders are widespread, affecting approximately one in eight individuals worldwide. Anxiety disorders and depressive disorders are the most frequently observed conditions in both males and females. Mental illnesses are the primary contributor to years lived with disabilities (YLDs), representing one sixth of all YLDs worldwide.
Today, psychiatric drugs are one of the most important treatment options for people suffering in this way. In fact, the introduction of psychiatric medications was one of the biggest breakthroughs in the history of the treatment of mental disorders. It significantly contributed to a shift in the treatment paradigm from long-term hospitalization to therapy in the patient's community settings. Having been improved over a number of years, today, psychiatric medications are the evidence-based gold standard for treating the majority of mental disorders.
At the same time, there is still a need for further research into their application in areas that have so far received little coverage, e.g., substance-misuse disorders, dementia, autism spectrum disorders, personality disorders, etc. The use of psychiatric drugs has also been criticized from a number of legitimate perspectives regarding their significant side effects, the potential abuse of certain substances, the related abandonment of other treatments (such as psychotherapy), or even the relegation of important individual and social problems to the simple and relatively inexpensive solution of taking a pill.
This Special Issue aims to highlight cutting-edge research, innovative approaches, and emerging trends in the development, efficacy, safety, utilization, and limitations of psychiatric medications.
I look forward to your valuable contributions.
Dr. Przemyslaw Waszak
Prof. Dr. Paweł Zagożdżon
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mental health treatment
- psychopharmacology
- antidepressants
- antipsychotics
- side effects
- safety profiles
- treatment resistance
- adherence issues
